US · Healthcare · Health Information Services
EPS came in at 0.05 against a street estimate of 0.06 — a miss of 16.7%.
Analysts rate Certara Inc a buy (4 buy, 9 hold, 0 sell out of 13) with an average price target of $8.71.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.34% |
| Deerfield Management Co | 4.93% |
| Haveli Investment Management LLC | 4.85% |
| Jefferies Financial Group Inc | 4.65% |
| Vanguard Portfolio Management, LLC | 4.63% |
| Dimensional Fund Advisors, Inc. | 3.95% |
| Vanguard Capital Management, LLC | 3.46% |
| State Street Corp | 3.16% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 CERTARA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company clarified a misstatement made during Q2 2026 earnings conference call on August 4, 2026 | 2026-08-07 |
| Quarterly report · Q2 2026 CERTARA, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Revenue (6 months): $187.363 million vs. $184.455 million prior year (+1.6%) • Revenu | 2026-08-04 |
| Results announced · Q3 2026 CERTARA, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenue Q2 2026: $93.3 million, up 1% year-over-year vs. $92.4 million in Q2 2025 | 2026-08-04 |
| Board / officer change · Q3 2026 CERTARA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics or performance data disclosed in this filing • This is a current report on | 2026-08-04 |
| Board / officer change · Q2 2026 CERTARA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No material financial figures or numerical guidance disclosed in this Form 8-K filing • Document | 2026-06-17 |
| Quarterly report · Q1 2026 CERTARA, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $106.915 million (vs. $106.004 million in Q1 2025) – essentially flat year- | 2026-05-11 |
| Proxy statement · Q2 2026 CERTARA, INC. PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Class III Directors – Vote FOR each of three nominee | 2026-04-03 |
| Annual report FY2025 CERTARA, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Certara, Inc. (ticker: CERT, Nasdaq) • Fiscal year ended: December 31, | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Sale of medical writing business to Veristat for $85 million closed Certara, Inc. announced on May 11, 2026 its Q1 2026 financial results and disclosed the completion of a significant business sale. On May 8, 2026, Certara sold its global medical writing and | 2026-05-11 |
| Sells global medical writing and regulatory services business to Veristat Certara, Inc. agreed to sell its global medical writing and regulatory services business to Veristat, LLC for $100 million in cash at closing, plus up to $35 million in additional earn-out p | 2026-04-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Certara Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.